FindTrial
Sign In

The real-world study for the change of early breast cancer diagnosis and treatment mode under the pandemic of Coronavirus Disease 2019 (COVID-19)

The real-world study for the change of early breast cancer diagnosis and treatment mode under the pandemic of Coronavirus Disease 2019 (COVID-19)

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2000033200
Enrollment
Unknown
Registered
2020-05-23
Start date
2020-01-01
Completion date
Unknown
Last updated
2020-05-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

breast cancer

Interventions

Case series:Nil

Sponsors

The Fifth Medical Center of Chinese General Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 90 Years

Inclusion criteria

Inclusion criteria: 1. Diagnosed as invasive breast cancer; 2. Those who have received at least one of the following treatments from January 1 to March 31, 2020, including neoadjuvant therapy, surgical treatment, and adjuvant therapy for early breast cancer; 3. The pathological results are clear and the diagnosis and treatment records are complete; 4. There is a clear record of the diagnosis and treatment place, the epidemic area and the history of contact with the Coronavirus Disease 2019 (COVID-19); 5. Informed consent.

Exclusion criteria

Exclusion criteria: 1. The pathological diagnosis is unclear or the diagnosis is ductal carcinoma in situ; 2. The date of diagnosis and treatment is unknown (including year, month and day).

Design outcomes

Primary

MeasureTime frame
DTT;NTS;STA;—

Countries

China

Contacts

Public ContactZe-Fei Jiang

The Fifth Medical Center of Chinese General Hospital

jiangzefei@csco.org.com+86 010 66947171

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026